Therapeutic strategies for leukodystrophy affected patients - LEUKOTREAT

Intranet Print the page
Therapeutic strategies for leukodystrophy affected patients - LEUKOTREAT (Home)
Flux RSS des actualités News


Documents to download

All documents prepared by the Ethics Research Group during LeukoTreat ...
See all news

Please enter your e-mail address

Last update : 09/02/2015

Home About LeukoTreat Presentation


Leukodystrophies (LDs) are inherited rare neurodegenerative diseases of the white matter and its main component, the myelin, which are affecting predominantly children. The overall prevalence of LDs is approximately 1 in 10 000 of the population and there are around 1 000 new cases per year in Europe.


Despite the achievement of remarkable advances in each individual LD in the past decade, there is no current curative therapy.


For more information on Leukodystrophies, please see the section Leukodystrophies.


The LeukoTreat Project

The LeukoTreat project thus aimed at promoting the development of therapeutic strategies for the largest number of LD affected patients and further applications to more common white matter (WM) disorders and neurodegenerative diseases. To that end, LeukoTreat combined the expertise of recognized European research teams in the field of WM diseases, high-technology SMEs, experts in medical ethics and LD patients and families associations.


Interview of Odile Boespflug-Tanguy – Project Coordinator

In this interview, the Project Coordinator Pr. Boespflug-Tanguy, from Robert-Debré Hospital (France), describes LeukoTreat and presents its objectives.